AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PRTA

Prothena: Q3 Earnings Snapshot

Prothena Corp. (PRTA) reported a Q3 loss of $16.5M, or 32 cents per share, beating analyst expectations of a 38 cents per share loss. The company generated $620K in revenue. According to Zacks Investment Research, the average estimate was for a larger loss.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 10:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Prothena: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PRTABullishLow
01

Why it matters

Earnings beat may prompt short‑term buying pressure, but long‑term outlook hinges on pipeline progress.

02

Market read

Micro‑cap biotech earnings with a modest beat; limited but actionable for niche traders.

03

What to watch

Revenue of only $620K highlights limited commercial traction.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Prothena is a Dublin‑based biotech focused on rare‑disease therapeutics.

Company-level read

Ticker impact

$PRTABullishMedium confidence
Context

Prothena reported Q3 loss of $16.5M, 32¢ per share, beating estimates of 38¢ loss.

Expected impact

likely modest upside as market prices in the earnings beat

Evidence & confidence

The loss was narrower than consensus, suggesting better-than-expected performance despite small revenue.

Market effects

Sector

Biotech earnings may influence peer valuations in the rare‑disease space.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

The loss, though better than expected, remains sizable; investors may remain cautious.

Key entities

  • company
    Prothena Corp.

    Biotech firm reporting Q3 results.

Read at source← All news

Related articles

$PRTAMedAI 8/10

Prothena Corporation plc: Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

Prothena reported Q3 2026 net loss of $16.5M and 9M net loss of $2.4M, with $272.2M in cash. Coramitug showed reduced hsCRP in Phase 2 trial. Roche and Novo highlight prasinezumab and coramitug for Parkinson's and ATTR-CM. Phase 3 trials expected to complete in 2029. Prothena has $650M in upfront payments and potential $2.25B in milestones. Preclinical programs include TDP-43 CYTOPE and PRX012-TfR.

finanznachrichten.de
$PRTAMed

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $12.0 million in the third quarter and net cash used in operating and investing activities was $8.9 million for the

SEC EDGAR 8-K
$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

tradingview.com
$PRTAMed

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provided by operating and investing activities was $3.2 million f

SEC EDGAR 8-K
$OXYHighAI 8/10

Occidental Petroleum (OXY) Q3 2026 Earnings Call Transcript

Occidental Petroleum (OXY) reported Q3 2026 earnings, highlighting advanced recovery techniques and strong operational performance. The company exceeded production guidance, with record outputs in New Mexico and the Powder River Basin. OXY also announced progress in its EOR initiatives, including sidetrack programs and CO2 offtake agreements. The company aims to add $4 billion in annual sustainable cash flow by 2030 through cost efficiencies and lower decline rates.

finance.yahoo.com